Cargando…

Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir

Although new heptatis C virus treatments have increased efficacy and improved safety profiles, they also come with risk. We describe a 66-year-old white man with Child-Pugh A cirrhosis secondary to heptatis C virus genotype 3, who suffered from an acute kidney injury after treatment with sofosbuvir...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashraf, Taha, Majoni, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496585/
https://www.ncbi.nlm.nih.gov/pubmed/28706960
http://dx.doi.org/10.14309/crj.2017.84
_version_ 1783248011955011584
author Ashraf, Taha
Majoni, William
author_facet Ashraf, Taha
Majoni, William
author_sort Ashraf, Taha
collection PubMed
description Although new heptatis C virus treatments have increased efficacy and improved safety profiles, they also come with risk. We describe a 66-year-old white man with Child-Pugh A cirrhosis secondary to heptatis C virus genotype 3, who suffered from an acute kidney injury after treatment with sofosbuvir and daclatasvir. Kidney biopsy demonstrated evidence of acute tubular interstitial nephritis consistent with a drug reaction. A trial of steroid therapy was effective, and his creatinine continues to improve significantly. Our case is the first report in the literature that highlights potentially serious interstitial nephritis associated with sofosbuvir and daclatasvir use.
format Online
Article
Text
id pubmed-5496585
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American College of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-54965852017-07-13 Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir Ashraf, Taha Majoni, William ACG Case Rep J Case Report Although new heptatis C virus treatments have increased efficacy and improved safety profiles, they also come with risk. We describe a 66-year-old white man with Child-Pugh A cirrhosis secondary to heptatis C virus genotype 3, who suffered from an acute kidney injury after treatment with sofosbuvir and daclatasvir. Kidney biopsy demonstrated evidence of acute tubular interstitial nephritis consistent with a drug reaction. A trial of steroid therapy was effective, and his creatinine continues to improve significantly. Our case is the first report in the literature that highlights potentially serious interstitial nephritis associated with sofosbuvir and daclatasvir use. American College of Gastroenterology 2017-07-05 /pmc/articles/PMC5496585/ /pubmed/28706960 http://dx.doi.org/10.14309/crj.2017.84 Text en Copyright © Ashraf et al. This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Case Report
Ashraf, Taha
Majoni, William
Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
title Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
title_full Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
title_fullStr Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
title_full_unstemmed Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
title_short Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
title_sort acute interstitial nephritis associated with sofosbuvir and daclatasvir
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496585/
https://www.ncbi.nlm.nih.gov/pubmed/28706960
http://dx.doi.org/10.14309/crj.2017.84
work_keys_str_mv AT ashraftaha acuteinterstitialnephritisassociatedwithsofosbuviranddaclatasvir
AT majoniwilliam acuteinterstitialnephritisassociatedwithsofosbuviranddaclatasvir